Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice
- 1 July 2019
- journal article
- research article
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 8 (9) , 685-697
Abstract
Aim: To analyze the impact of sacubitril/valsartan on functional class, surrogate parameters and clinical outcomes in clinical practice. Methods: Retrospective study of patients with heart failure and reduced ejection fraction that started treatment with sacubitril/valsartan. Results: 149 patients (70.7 ± 9.6 years) were included. At baseline, 83.9, 15.4 and 0.7% were taking sacubitril/valsartan 24/26, 49/51 and 97/103 mg, respectively. After 316.1 ± 155.9 days, these numbers moved to 38.9, 39.6, 12.8% (8.7% discontinued). Sacubitril/valsartan improved functional class (from 2.3 ± 0.6 to 1.8 ± 0.5; p < 0.001), increased ejection fraction (from 31.2 ± 7.0 to 37.3 ± 10.5%; p < 0.001) and reduced NT-proBNP (from 3884 ± 4871 to 1975.3 ± 3006.6 pg/ml; p = 0.0001). Rates of any event, cardiovascular death and heart failure hospitalization/decompensation were 13.2 events/100 patient-years. Conclusion: Sacubitril/valsartan is effective and safe in routine practice.Keywords
This publication has 40 references indexed in Scilit:
- Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devicesHeart Rhythm, 2018
- Impact of Systolic Blood Pressure on the Safety and Tolerability of Initiating and Up-Titrating Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction: Insights from the TITRATION StudyEuropean Journal of Heart Failure, 2017
- Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectivesVascular Health and Risk Management, 2017
- Health-Related Quality of Life Outcomes in PARADIGM-HFCirculation: Heart Failure, 2017
- Carbohydrate Antigen-125–Guided Therapy in Acute Heart FailureJACC: Heart Failure, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Understanding the Epidemic of Heart Failure: Past, Present, and FutureCurrent Heart Failure Reports, 2014
- Association Between Performance Measures and Clinical Outcomes for Patients Hospitalized With Heart FailureJAMA, 2007
- Acute Heart Failure: Clinical Presentation, One-Year Mortality and Prognostic FactorsEuropean Journal of Heart Failure, 2005